Marinus Pharmaceuticals, Inc.

NASDAQ:MRNS

1.51 (USD) • At close September 18, 2024
Bedrijfsnaam Marinus Pharmaceuticals, Inc.
Symbool MRNS
Munteenheid USD
Prijs 1.51
Beurswaarde 83,176,840
Dividendpercentage 0%
52-weken bereik 1.05 - 11.26
Industrie Biotechnology
Sector Healthcare
CEO Dr. Scott N. Braunstein M.D.
Website https://marinuspharma.com

An error occurred while fetching data.

Over Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute

Vergelijkbare Aandelen

MoonLake Immunotherapeutics logo

MoonLake Immunotherapeutics

MLTX

53.11 USD

Pliant Therapeutics, Inc. logo

Pliant Therapeutics, Inc.

PLRX

12.5 USD

DermTech, Inc. logo

DermTech, Inc.

DMTK

0.094 USD

Immunic, Inc. logo

Immunic, Inc.

IMUX

1.79 USD

Kronos Bio, Inc. logo

Kronos Bio, Inc.

KRON

0.92 USD

Personalis, Inc. logo

Personalis, Inc.

PSNL

5.52 USD

Sanara MedTech Inc. logo

Sanara MedTech Inc.

SMTI

31.11 USD

Lyra Therapeutics, Inc. logo

Lyra Therapeutics, Inc.

LYRA

0.274 USD

Tactile Systems Technology, Inc. logo

Tactile Systems Technology, Inc.

TCMD

13.77 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)